Ipratropium Bromide Patent Expiration
Ipratropium Bromide was first introduced by Boehringer Ingelheim Pharmaceuticals Inc
Ipratropium Bromide Patents
Given below is the list of patents protecting Ipratropium Bromide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Atrovent Hfa | US8474447 | Inhaler device | Jan 17, 2030 | Boehringer Ingelheim |
| Atrovent Hfa | US6739333 | Stainless steel canister for propellant-driven metering aerosols |
May 26, 2020
(Expired) | Boehringer Ingelheim |
| Atrovent Hfa | US6983743 | Stainless steel canister for propellant-driven metering aerosols |
May 26, 2020
(Expired) | Boehringer Ingelheim |
| Atrovent Hfa | US5683677 | Medicinal aerosol formulations |
Nov 04, 2014
(Expired) | Boehringer Ingelheim |
| Atrovent Hfa | US5676930 | Stabilized medicinal aerosol solution formulations |
Oct 14, 2014
(Expired) | Boehringer Ingelheim |
Ipratropium Bromide's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Ipratropium Bromide:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Effect of Ipratropium Bromide on EILO | Cook Children's Health Care System | NA |
NOT YET RECRUITING
(May 1, 2026)
| PHASE2 |